Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

NCT02225132 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Hydroxyurea

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)